Board of Directors
The Board of Directors comprises 5 members including 2 executive members
Chairman of the Board - Chief Executive OfficerIgnacio Faus, Ph.D., MBA
Dr. Ignacio Faus joined NFL Biosciences in 2019 as an investor, then the management team in early 2021 as a director and CEO of NFL Biosciences. In February 2023 he was appointed Chairman of the Board of Directors.
Dr. Ignacio Faus has 27 years' experience in large and medium-sized pharmaceutical companies, as well as in private and listed biotech companies: Bristol Myers Squibb, Grupo Uriach, Ferrer and co-founder in 2006 and Managing Director of Palau Pharma (sold in 2013). In recent years, Ignacio Faus has also been a director of several private and listed biotech companies and private equity funds in Europe and the United States.
Ignacio holds a PhD in Biochemistry (Indiana University, USA) and an MBA in Entrepreneurship and Finance from the Kellogg School of Management (Northwestern University, USA).
Board Member - Co-Founder and Chief Operating OfficerBruno Lafont, M.Sc., Executive MBA
Bruno Lafont co-founded NFL Biosciences in 2009, and is in charge of the structuring and technical development of NFL Biosciences and its various projects.
Previously, Bruno spent 12 years on the management team of PCM, an international French industrial group, as Innovation Director from 1999 to 2004, then as President and in charge of setting up the group's US subsidiary in Houston (Texas) from 2004 to 2009.
Bruno holds an engineering degree in biochemistry from the Institut National des Sciences Appliquées (INSA) in Toulouse, a Master's degree in management from EMLyon, and an Executive MBA from the Ecole Polytechnique Fédérale de Lausanne and HEC Lausanne.
Board Member - Expert in Intellectual PropertyFrancis Ahner, M.Sc., Patent Attorney
Francis Ahner is Honorary President of the International Federation of Intellectual Property Attorneys (FICPI).
He holds a degree in chemical engineering from ENSCS, a Master's degree in Law, Economics and Management from the University of Strasbourg, and a diploma from the Centre d'Etudes Internationales de la Propriété Intellectuelle (CEIPI), where he taught for many years.
In 1972, he joined Cabinet Regimbeau, where he became a partner. It was with this firm that he spent his entire career as an Intellectual Property Attorney and European Patent Attorney, advising leading French and foreign private companies and public bodies in the chemical field, and more specifically in pharmaceuticals and cosmetology. He has thus acquired in-depth experience in international litigation relating to the acquisition and defense of patent rights in France and abroad.
Board Member - Expert in go to market commercializationDominique Côté
Dominique graduated in genetics and biotechnology from the Université du Québec à Montréal, has a certificate in administration from Laval University and in leadership from Cornell University (USA).
After spending time in research, she joined the pharmaceutical industry where she spent 30 years of her career with organizations such as Novartis, Pfizer, Zoetis and UCB. As a Chief Commercial Officer, she managed teams in more than 36 countries leading strategy optimization and deployment of new go to market models. With international experience and diverse knowledge of cultures and business; In 2018, she found her consulting firm, Cosawi,to help companies with their commercial excellence strategies,customer / patient engagement models and is an executive coach.Speaker and author in numerous business journals, in 2023 she is recognized as CEO of the Year for business transformations by AI – Influential businesswomen.
Board Member - Expert in Clinical DevelopmentYannick Plétan, M.D.
Yannick Plétan holds degrees in pneumology, immunology, clinical pharmacology and pharmacokinetics - post-doctorate at INSERM and visiting professor at the University of California Davis. After practicing hospital medicine for several years, he joined the pharmaceutical industry, where he held senior management positions for 20 years in R&D and medical affairs at Sanofi, Institut de Recherche Pierre Fabre, Pfizer and Roche-Genentech. He played a central role in the creation and worldwide development of the nicotine patch, and in the later development and launch of Chantix®.
About Us
Products
Investors
© NFL Biosciences 2023 – Mentions légales – Confidentialités & Conditions générales d’utilisation – Plan du site
Fait par Studio Vitamine